Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inozyme Pharma

1.01
+0.03063.12%
Volume:385.94K
Turnover:389.02K
Market Cap:64.88M
PE:-0.62
High:1.04
Open:0.9928
Low:0.9766
Close:0.9794
Loading ...

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

GlobeNewswire
·
21 Feb

Inozyme Pharma Is Maintained at Overweight by Wells Fargo

Dow Jones
·
13 Jan

Inozyme Pharma: Promising Pipeline and Market Potential Supports Buy Rating

TIPRANKS
·
11 Jan

Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)

TIPRANKS
·
11 Jan

Positive Outlook for Inozyme Pharma Amidst Pipeline Advancements and Undervaluation

TIPRANKS
·
11 Jan

Inozyme price target raised to $16 from $14 at H.C. Wainwright

TIPRANKS
·
11 Jan

Inozyme Pharma, Inc. : H.c. Wainwright Raises Target Price to $16 From $14

THOMSON REUTERS
·
11 Jan

BRIEF-Inozyme Pharma Reports Positive Interim Data For INZ-701 And Key Program Updates

Reuters
·
10 Jan

Inozyme Pharma Announces Positive Interim Data for Inz-701 in Infants and Young Children With Enpp1 Deficiency and Key Program Updates

THOMSON REUTERS
·
10 Jan

Inozyme Pharma Inc - 80% of Infants Treated With Inz-701 Survived Beyond First Year

THOMSON REUTERS
·
10 Jan

Inozyme Pharma Inc - Inz-701 Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
10 Jan

Inozyme Pharma Inc - No Radiographic Evidence of Rickets in Patients Evaluated Beyond One Year

THOMSON REUTERS
·
10 Jan

Inozyme Pharma Inc - Aims to Initiate Aspire Trial in Early 2026

THOMSON REUTERS
·
10 Jan

Raymond James Initiates Inozyme Pharma at Outperform With $26 Price Target

MT Newswires Live
·
12 Dec 2024

Inozyme Pharma Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $26

THOMSON REUTERS
·
12 Dec 2024

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Zacks
·
13 Nov 2024

Inozyme Pharma Receives Buy Rating for Promising Pipeline and Strategic Advancements

TIPRANKS
·
06 Nov 2024

Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham

Dow Jones
·
06 Nov 2024

U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos

Reuters
·
06 Nov 2024

Inozyme Pharma Inc : Jefferies Cuts Target Price to $15 From $17

THOMSON REUTERS
·
06 Nov 2024